Shared on 16 Aug 25

Fair value Decreased 12%

Schrödinger’s consensus price target has been revised downward to $28.20, reflecting analyst concerns over disappointing progress in its proprietary drug portfolio and broader sector headwinds, partially offset by steady performance in its software business. Analyst Commentary Bearish analysts expressed concerns over disappointing updates from Schrodinger's proprietary drug portfolio, particularly lackluster progress in its early Phase 1 assets, which were previously anticipated to attract significant partner interest.

Read more

0 votes1Share

Shared on 01 May 25

Fair value Decreased 12%

Read more

0 votesShare

Shared on 24 Apr 25

Fair value Increased 1.42%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

Fair value Increased 1.74%

AnalystConsensusTarget has decreased revenue growth from 24.1% to 21.2%.

Read more

0 votesShare

Shared on 09 Apr 25

Fair value Increased 8.86%

AnalystConsensusTarget has increased profit margin from 12.2% to 14.7% and decreased future PE multiple from 58.4x to 48.7x.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Increased 8.83%

Read more

0 votesShare

Shared on 26 Mar 25

Fair value Decreased 9.72%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare